The Trump administration is doubling down on efforts to revamp the federal discount drug program — a major flashpoint between Big Pharma and hospitals. The so-called 340B program has been mired in litigation, most recently over administration efforts to let drugmakers carry out price reductions through rebates instead of cutting prices at the front end. After a court halted the attempt on procedural grounds, federal health officials this month laid the groundwork to reintroduce changes that providers say could cost them hundreds of millions of dollars.
Read the full article: HHS Takes Another Swing at Drug Discount Overhaul //
Source: https://www.axios.com/2026/02/23/hhs-340b-drug-discount-overhaul